RareWays is a research directory. It helps you understand the science. It is not medical advice. Always discuss your care options with your healthcare team.
Coverage: 2020-01-01 onwards, with up to 300 results per query from PubMed and Europe PMC and separate limits on other sources. This is a selected index, not a complete literature search.
Updates are delayed or unverified. Check original sources for the latest information.
Your saved research and appointment questionsView recorded trial and retraction changes
Extranodal Nasal NK/T Cell Lymphoma: Research Summary
Printed from RareWays (rareways.org)
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Allogeneic versus autologous stem cell transplantation for extranodal NK/T-Cell lymphoma: A systematic review and meta-analysis.
Tominaga Ryutaro et al., Bone marrow transplantation (16 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42888215/
- 2.
Clinicopathological Analysis of Extranodal NK/T-Cell Lymphoma with Rare Extranodal Localizations: Experience from a Tertiary Care Cancer Center in India
Sadaf Haiyat et al., SN Comprehensive Clinical Medicine (6 October 2026)
https://doi.org/10.1007/s42399-026-02713-0
- 3.
Role of Serum Metabolites in Mediating the Effect of Circulating Inflammatory Proteins on NK/T Cell Lymphoma.
Lou Dian et al., Current medicinal chemistry (6 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42864932/
- 4.
414 Extranodal NK/T-cell Lymphoma with Skin Rash as the Initial Manifestation
Xinying Cai et al., Journal of Investigative Dermatology (1 October 2026)
https://doi.org/10.1016/j.jid.2026.09.439
- 5.
Prognostic Significance of Deubiquitinase OTUD7B in NK/T-Cell Lymphoma.
Liu Yizhen et al., Asia-Pacific journal of clinical oncology (1 October 2026)
https://pubmed.ncbi.nlm.nih.gov/41283788/
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Extranodal Nasal NK/T Cell Lymphoma
Extranodal nasal NK/T cell lymphoma is a rare cancer of the immune system that most often starts in the nose or upper airway, though it can arise elsewhere in the body. It is strongly linked to Epstein-Barr virus infection. Treatment usually combines radiotherapy with chemotherapy, and newer approaches such as immunotherapy are being studied.
This overview is general information, not an individual medical assessment. Research is selected automatically and may include mismatches. How we select and explain research.
Most Recent Research
Common Questions
What is Extranodal Nasal NK/T Cell Lymphoma?
Extranodal nasal NK/T cell lymphoma is a rare cancer of the immune system that most often starts in the nose or upper airway, though it can arise elsewhere in the body. It is strongly linked to Epstein-Barr virus infection. Treatment usually combines radiotherapy with chemotherapy, and newer approaches such as immunotherapy are being studied.
How many clinical trials are available for Extranodal Nasal NK/T Cell Lymphoma?
RareWays currently indexes 147 clinical trials for Extranodal Nasal NK/T Cell Lymphoma, of which 15 are actively recruiting. These counts cover indexed trials across countries, not just your country. An Australian site does not necessarily mean that site is recruiting. Check locations, eligibility and current availability with the study team.
Where does the research data for Extranodal Nasal NK/T Cell Lymphoma come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is refreshed automatically every day. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Extranodal Nasal NK/T Cell Lymphoma.
Your email and selected disease are stored for these updates. Unsubscribe any time. Privacy and deletion.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.